NCT05213572Recruiting

Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies

Source: ClinicalTrials.gov · Last updated 22 Oct 2026

Brief summary (registry, in English)

Background: People with sickle cell disease (SCD) have problems with their heart, brain, kidneys, liver, and lungs as they age. These problems may improve after transplant. Researchers want to learn how and why this happens. Objective: To study the benefits of treatments that are intended to cure SCD. Eligibility: People aged 18 and older with SCD who are either receiving curative therapy in the next 3 months or don t have any plans to receive a curative therapy in the next 2 years. Design: At their first visit, participants will be screened with their medical history and a physical exam. Participants will then have a baseline visit. This will take about a week to complete and will include: Blood and heart tests MRI of the brain, heart, and lungs. Participants will lie on a bed that will move into the MRI scanner. Special padding may be placed around their head to keep it still. Interactive games. Participants will complete computer games that test memory, attention, problem solving, language, spatial orientation, processing speed, and emotion. Questionnaire rating quality of life Iothalamate test. An IV catheter will be placed into a vein. A contrast agent will be injected through the IV. Blood will then be collected at different time points. Lung function tests and a 6-minute walk test Vibration controlled transient elastography. A probe placed on the abdomen will measure liver scarring. DOS test. A light attached to the finger or toe will measure blood oxygen. Participants will have an end-of-study visit about 2 years after their baseline visit. This will include repeats of the baseline visit tests.

Status (registry): Recruiting
Study type: Observational
Enrollment: 200 (estimated)
First submitted: 27 Jan 2022
Start date: 24 Mar 2022
Primary completion date: 1 Jun 2035
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Diseases: Sickle cell disease
NCT number: NCT05213572

What you commit to

Study type: Observational
Planned participants: 200
From 24 Mar 2022 to the primary completion date, 1 Jun 2035
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Prior transplantation (including but not limited to HSCT and kidney transplant)
Implanted metal object that is not compatible with MRI (e.g.: cerebral aneurysm clip, cochlear implant, or pacemaker)

Other illness

Uncontrolled infection or acute illness

Lab values

Patients with allergy to iodine or iodinated contrast solutions will not undergo Iothalamate or Iohexol GFR clearance testing but can undergo the other deep phenotype testing

Other

All individuals meeting any of the exclusion criteria at baseline will be excluded from study participation.
Pregnant or breastfeeding
Patients with a pacemaker or automated implantable cardioverter defibrillator will not undergo VCTE but can enroll and undergo the other deep phenotype testing as long as the device is compatible with MRI and MRI testing can be performed
Patients requiring peritoneal or hemodialysis

Criteria the registry did not label

INCLUSION CRITERIA:
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged \>=18 years
Patients with current or previous diagnosis of any type of SCD (including HbSS, HbSC, HbSbeta\^0-thal, HbSbeta\^+-thal) who:
- plan to receive an allogeneic HCT or gene therapy,
- Or
- are receiving non-curative treatment (standard of care or investigational) and who do not plan to receive an allogeneic HCT or gene therapy
Ability to travel to the NIH Clinical Center
Ability of subject to understand a written informed consent document.
At least one of the following eligibility criteria:
- History of stroke (including silent stroke) or abnormal transcranial doppler examination (\>= 200 m/s)
- Progression of central nervous system vasculopathy on MRA
- History of SCD-related renal insufficiency defined as nephrotic syndrome OR creatinine clearance \< 60mL/min OR a creatinine level \>=1.3 mg/dL AND kidney biopsy consistent with sickle cell nephropathy
- Tricuspid regurgitant velocity \>= 2.5 m/s
- Recurrent tricorporal priapism defined as at least 2 episodes of an erection lasting \> 4 hours involving the corpora cavernosa and corpus spongiosa
- SCD-associated liver disease defined as EITHER ferritin \> 1000 mcg/L OR direct bilirubin \> 0.4 mg/dL
- \> 1 hospitalization per year for vaso-occlusive crises while receiving hydroxyurea treatment
- A history of 2 or more acute chest syndrome episodes in the participant's lifetime.
- Avascular necrosis of 2 or more joints
- Red cell alloimmunization (delayed hemolytic transfusion reaction or significant red blood cell alloimmunization that makes transfusion difficult).
- Administration of regular red blood cell (RBC) transfusion therapy (\>=8 red cell transfusions in the previous 12 months) to prevent SCD complications (i.e. pain, stroke, or acute chest syndrome).
- Eligible for an allogeneic HCT or gene therapy at an outside transplant center.

Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

Site	City	Country	Site status
National Institutes of Health Clinical Center Coordinator of this site? Confirm its status	Bethesda	United States	Recruiting

This page is information, not medical advice. Discuss any trial with your doctor.